Analytical Data
-
Gene name
NPAS2
- Application
-
Alternative Names
Basic helix loop helix PAS protein MOP4; Basic-helix-loop-helix-PAS protein MOP4; bHLHe9; class E basic helix loop helix protein 9; Class E basic helix-loop-helix protein 9; FLJ23138; Member of PAS protein 4; Member of PAS superfamily 4; MGC71151; MOP4; Neuronal PAS domain containing protein 2; Neuronal PAS domain protein 2; Neuronal PAS domain-containing protein 2; Neuronal PAS2; NPAS2; NPAS2_HUMAN; PAS domain containing protein 4; PAS domain-containing protein 4; PASD4
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99743
-
Expression Region
1-824 aa
-
AA Sequence
MDEDEKDRAKRASRNKSEKKRRDQFNVLIKELSSMLPGNTRKMDKTTVLEKVIGFLQKHNEVSAQTEICDIQQDWKPSFLSNEEFTQLMLEALDGFIIAVTTDGSIIYVSDSITPLLGHLPSDVMDQNLLNFLPEQEHSEVYKILSSHMLVTDSPSPEYLKSDSDLEFYCHLLRGSLNPKEFPTYEYIKFVGNFRSYNNVPSPSCNGFDNTLSRPCRVPLGKEVCFIATVRLATPQFLKEMCIVDEPLEEFTSRHSLEWKFLFLDHRAPPIIGYLPFEVLGTSGYDYYHIDDLELLARCHQHLMQFGKGKSCCYRFLTKGQQWIWLQTHYYITYHQWNSKPEFIVCTHSVVSYADVRVERRQELALEDPPSEALHSSALKDKGSSLEPRQHFNALDVGASGLNTSHSPSASSRSSHKSSHTAMSEPTSTPTKLMAEASTPALPRSATLPQELPVPGLSQAATMPAPLPSPSSCDLTQQLLPQTVLQSTPAPMAQFSAQFSMFQTIKDQLEQRTRILQANIRWQQEELHKIQEQLCLVQDSNVQMFLQQPAVSLSFSSTQRPEAQQQLQQRSAAVTQPQLGAGPQLPGQISSAQVTSQHLLRESSVISTQGPKPMRSSQLMQSSGRSGSSLVSPFSSATAALPPSLNLTTPASTSQDASQCQPSPDFSHDRQLRLLLSQPIQPMMPGSCDARQPSEVSRTGRQVKYAQSQTVFQNPDAHPANSSSAPMPVLLMGQAVLHPSFPASQPSPLQPAQARQQPPQHYLQVQAPTSLHSEQQDSLLLSTYSQQPGTLGYPQPPPAQPQPLRPPRRVSSLSESSGLQQPPR
-
Molecular Weight
118.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NPAS2 (Neuronal PAS Domain Protein 2) is a member of the PAS family of proteins and plays a crucial role in the regulation of circadian rhythms and neurobiology. This transcription factor is primarily expressed in the brain and is essential for the synchronization of circadian cycles with environmental cues. Dysregulation of NPAS2 has been linked to various neuropsychiatric disorders, including depression and bipolar disorder. Researchers have shown that NPAS2 interacts with several signaling pathways, influencing gene expression related to circadian rhythms and neuronal function. Given its pivotal role in maintaining circadian homeostasis, recombinant NPAS2 protein has become a focus of study for better understanding its functions and potential therapeutic targets. By producing NPAS2 as a recombinant protein, scientists can investigate its structural characteristics, binding interactions, and regulatory mechanisms in a controlled environment. This research is vital, as it may lead to novel interventions for circadian-related disorders and further elucidate the complex biology of neuronal signaling and behavior. The study of NPAS2, particularly in its recombinant form, provides valuable insights into the molecular underpinnings of circadian clock regulation and offers promising avenues for future therapeutic development.
